FBLG
FibroBiologics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.94
−2.77%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.98
From 52W high−89.19%
Volume185728.00
Market cap$6.69M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.98
From 52W high
−89.19%
Volume
185728.00
Market cap
$6.69M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
32.0
MomentumView details →
1D Return
−2.77%
YTD Return
−78.72%
SummaryUpdated Jun 1, 2026
FibroBiologics, Inc. (NASDAQ:FBLG) is a clinical-stage biotechnology company founded in 2021 and headquartered in Houston, Texas. The company went public in February 2024 and focuses on developing innovative cell therapy treatments using fibroblasts, a type of connective tissue cell. As a pre-revenue biotech firm, FibroBiologics is currently advancing multiple therapeutic candidates through clinical trials, targeting conditions ranging from spinal disc degeneration to multiple sclerosis and cancer treatment.
Similar companies
Latest newsMore news →
IP Australia issued a Notice of Acceptance for FibroBiologics’ Australian patent application covering a cellular blend intended to regenerate cartilage cells in degenerated spinal discs.5d agoThe European Patent Office granted European Patent No. EP to FibroBiologics covering methods of enhancing fibroblast therapeutic activity using platelet rich plasma and cytokines.20d ago